A leading expert with 15+ years’ experience in antibody engineering and currently managing a core science team with various academic and industry collaborations. Utilising proprietary techniques developed through her research, she has invented, and progressed antibody leads into PoC animal models and immunodiagnostic development (including £3 M Alzheimer’s programme). Awarded the prestigious Royal Society of Edinburgh-Scottish Enterprise Commercialisation Fellowship with mentorship from high-profile biotech and business entrepreneurs whilst working within Wyeth/Pfizer.

An international authority on fungal cell wall biosynthesis, antifungal drug resistance and tolerance mechanisms. Her research focusses on understanding the role of various cell wall proteins in host interactions and mechanisms of wall remodelling under cellular stress. With a wealth of expertise in project management (Director of the Wellcome Trust Strategic Award in Medical Mycology & Fungal Immunology 2019-2020, £5 M with multiple partners) and is a partner on several EU Horizon 2020 & Innovative Training Networks.

A seasoned executive serving as Chairman and Director for several biotechs and brings 30 years of experience in VC and Fortune 500 companies. He has led the negotiation of several licensing deals and helped early-stage companies to raise £55 M+ in investment. Previously CEO of GlySure and Tensys Medical taking the company to trade sale.  He was Chair of Elasmogen Ltd securing a £10.3 M Series A round (and grant) for the company.

Prof Porter has a proven track record in the commercialisation of academic assets and creation of spinouts and is currently the Chair of Roslin Technologies Ltd, CTO of Elasmogen Ltd and non-Exec on Microplate Dx Ltd. He has been part of Boards that have raised over £50+ M with £20+ M raised in 2022. Prof Porter has also successfully exited businesses to pharma.

Over 20 years’ experience in biologics discovery, development manufacture and commercialisation with companies ranging from small SMEs to large matrixed commercial manufacturing organisations. Dan has assisted in the early development of antibody therapeutics and on multiple partnered IND projects through to commercialisation.

An experienced Chartered Account, CFO and Corporate Finance executive with nearly 30 years’ commercial experience in investment and financial management. He is a principal in several businesses across a broad spectrum of industry sectors, with executive roles covering strategy & planning, finance, HR, operational management and investor relations management.